Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab Extension Study in Adults With XLH
NCT03920072Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Started Mar 2019; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT03920072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920072.